First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value by Wim A. Wuyts et al.
First Data on Efficacy and Safety of Nintedanib in Patients
with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity
of £50 % of Predicted Value
Wim A. Wuyts1 • Martin Kolb2 • Susanne Stowasser3 • Wibke Stansen3 •
John T. Huggins4 • Ganesh Raghu5
Received: 30 March 2016 / Accepted: 14 June 2016 / Published online: 4 July 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract In the Phase III INPULSIS trials, 52 weeks’
treatment with nintedanib reduced decline in forced vital
capacity (FVC) versus placebo in patients with idiopathic
pulmonary fibrosis (IPF). Patients who completed the
INPULSIS trials could receive nintedanib in an open-
label extension trial (INPULSIS-ON). Patients with
FVC\50 % predicted were excluded from INPULSIS,
but could participate in INPULSIS-ON. In patients with
baseline FVC B50 % and[50 % predicted at the start of
INPULSIS-ON, the absolute mean change in FVC from
baseline to week 48 of INPULSIS-ON was -62.3 and
-87.9 mL, respectively (n = 24 and n = 558, respec-
tively). No new safety signals were identified in
INPULSIS-ON compared with INPULSIS. The decline
in FVC in INPULSIS-ON in both subgroups by baseline
FVC % predicted was similar to that in INPULSIS,
suggesting that nintedanib may have a similar effect on
disease progression in patients with advanced disease as in
less advanced disease.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic form of
interstitial pneumonia associated with worsening dyspnoea
and progressive decline in lung function [1]. Measuring
decline in forced vital capacity (FVC) is an established
method for assessing disease progression in patients with
IPF and is a predictor of mortality [2, 3].
Nintedanib, an intracellular inhibitor of tyrosine kinases
[4, 5], is approved for the treatment of IPF in several
countries and regions, including the US, Europe [6, 7] and
Japan. In the most recent international clinical practice
guideline, nintedanib received a conditional recommenda-
tion for use in the treatment of IPF, taking into account
individual patients’ preferences [8].
The INPULSIS trials were two replicate, randomised,
placebo-controlled trials that assessed the efficacy and
safety of 52 weeks’ treatment with nintedanib 150 mg
twice daily (bid) in patients with IPF [9]. To be eligible to
enter the INPULSIS trials, patients had to be C40 years
old and to have an FVC of C50 % predicted, diffusing
capacity of the lung for carbon monoxide of 30–79 %
predicted and forced expiratory volume in 1 s/FVC ratio of
C0.7. In both trials, nintedanib slowed disease progression
by reducing the annual rate of decline in FVC by approx-
imately 50 % [9]. Diarrhoea was the most frequent adverse
event in the nintedanib group, reported in 62.4 % of
patients treated with nintedanib and 18.4 % on placebo [9].
Patients who completed the INPULSIS trials were
eligible to enter an open-label extension trial known as
INPULSIS-ON (NCT01619085), irrespective of their
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FVC. Therefore, patients with FVC B50 % predicted could
participate in INPULSIS-ON. We assessed the decline in
FVC and safety of nintedanib in INPULSIS-ON in
patients who started this open-label extension trial with
FVC B50 % and[50 % predicted.
Methods
All patients who completed the 52-week treatment period
and follow-up visit in an INPULSIS trial were eligible to
enter INPULSIS-ON. All patients provided informed
consent before entering INPULSIS-ON. Per protocol, the
off-treatment period between the end of INPULSIS and
start of INPULSIS-ON could be 4–12 weeks. All patients
in INPULSIS-ON received open-label nintedanib.
Patients who were receiving of nintedanib 150 mg bid or
its matching placebo at the end of INPULSIS received of
nintedanib 150 mg bid in INPULSIS-ON, while patients
receiving nintedanib 100 mg bid or its matching placebo at
the end of INPULSIS could receive either nintedanib 100
or 150 mg bid in INPULSIS-ON. The dose was decided
based on discussion between the patient and investigator.
As in the INPULSIS trials, dose reduction to 100 mg bid
or treatment interruption was allowed to manage adverse
events [9]. The primary outcome was the incidence of
adverse events. Change in FVC was a secondary outcome
measure. FVC measurements were taken at the start of
INPULSIS-ON, at weeks 2, 4, 6, 12, 24, 36, 48, 64, every
16 weeks thereafter until the end-of-treatment visit, and at
a follow-up visit planned for 28 days after the last intake of
the study drug.
The first patient was enrolled into INPULSIS-ON in
July 2012. The trial is ongoing. We conducted a post hoc,
exploratory subgroup analysis in patients with FVC B50 %
and[50 % predicted at the start of INPULSIS-ON based
on an interim database lock in November 2014. The
analyses were performed for all patients treated in
INPULSIS-ON, irrespective of the treatment they had
received in INPULSIS. Absolute and relative declines in
FVC in INPULSIS-ON were based on observed cases.
Safety was assessed via reporting of adverse events
according to the Medical Dictionary for Regulatory
Activities (MedDRA). All analyses in INPULSIS-ON
were descriptive.
Results
A total of 1061 patients were treated in the INPULSIS trials
(638 with nintedanib, 423 with placebo) [9]. Of 807 patients
who completed the INPULSIS trials, 734 (91 %) patients
were treated in INPULSIS-ON (430 continuing nintedanib,
304 initiating nintedanib). Baseline FVC % predicted values
were missing for three patients at the start of INPULSIS-ON
(one continuing nintedanib, two initiating nintedanib). At the
start of INPULSIS-ON, 41 patients had FVC B50 % pre-
dicted (23 continuing nintedanib, 18 initiating nintedanib) and
690 patients had FVC[50 % predicted (406 continuing
nintedanib, 284 initiating nintedanib). Baseline characteristics
at the start of INPULSIS and INPULSIS-ON are presented
in Table 1. Mean (SD) exposure in INPULSIS-ON was 16.7
(7.0) months. Mean (SD) duration of exposure in patients with
FVC B50 % and[50 % predicted at the start of INPULSIS-
ON was 12.1 (8.6) and 17.0 (6.8) months, respectively.
FVC values from 24 patients with FVC B50 % pre-
dicted and 558 patients with FVC[50 % predicted at the
start of INPULSIS-ON were available at week 48. The
absolute change in FVC from baseline of INPULSIS-ON
to week 48 of INPULSIS-ON was of a similar magnitude
in patients with FVC B50 % and[50 % predicted at the
start of INPULSIS-ON (mean [SEM] -62.3 [63.1] and
-87.9 [10.0] mL, respectively) (Fig. 1a). Relative changes
in FVC from baseline were also similar between subgroups
(Fig. 1b). In both subgroups, the absolute change in FVC
from baseline to week 48 of INPULSIS-ON was of a
similar magnitude to the absolute change from baseline of
INPULSIS to week 52 of INPULSIS in patients treated
with nintedanib in INPULSIS (mean [SEM] -88.9
[11.6] mL).
A summary of the adverse events in INPULSIS and
INPULSIS-ON is presented in Table 2. The most fre-
quent adverse event in INPULSIS-ON was diarrhoea,
reported in 46.3 % and 64.6 % of patients with baseline
FVC B50 % and[50 % predicted, respectively. Diarrhoea
led to treatment discontinuation in 4.9 % and 5.4 % of
patients in these subgroups, respectively. A higher pro-
portion of patients with baseline FVC B50 % predicted
compared with FVC[50 % predicted had adverse events
of dyspnoea (24.4 % vs. 12.8 %) and progression of IPF
(34.1 % vs. 15.1 %), which included disease worsening
and acute exacerbations. Progression of IPF led to drug
discontinuation in 17.1 % and 5.4 % of patients with
baseline FVC B50 % and [50 % predicted, respectively.
A higher proportion of patients with baseline FVC B50 %
predicted than FVC[50 % predicted had serious adverse
events (63.4 % vs. 39.3 %) and fatal adverse events
(22.0 % vs. 9.6 %).
Discussion
In this interim analysis of data from INPULSIS-ON, the
open-label extension of the INPULSIS trials, the absolute
decline in FVC over 48 weeks was similar in patients with
FVC B50 % and [50 % predicted at the start of
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INPULSIS-ON. In both subgroups, the decline in FVC in
INPULSIS-ON was similar to the decline in FVC in
patients treated with nintedanib in the preceding
INPULSIS trials. These results suggest that first, the
effect of nintedanib on slowing disease progression is
maintained beyond 52 weeks and, second, that patients
with severely impaired FVC may receive the same benefit
from nintedanib on reduction in FVC decline as patients
with less severe impairment. In general, the adverse event
profile was similar in both subgroups, with no new safety
signals identified in INPULSIS-ON compared to
INPULSIS, but as might be expected, serious adverse
events and fatal adverse events were more common in
patients with more advanced disease, as were adverse
events of dyspnoea and disease progression.
These are the first data to be published on the effects of
antifibrotic therapy in patients with FVC\50 % predicted.
Patients with FVC\50 % predicted are usually excluded
from clinical trials in IPF [9–13] as it is thought that it is
too difficult to retain patients with severe lung function
impairment in trials. However, studying this patient pop-
ulation is important, as patients with IPF and severely










Age, years, mean (SD) 66.6 (8.1) 67.0 (7.9) 66.9 (8.3) 67.1 (7.8)
Male, n (%) 507 (79.5) 334 (79.0) 32 (78.0) 554 (80.3)
Race, n (%)
White 360 (56.4) 248 (58.6) 29 (70.7) 401 (58.1)
Asian 194 (30.4) 128 (30.3) 8 (19.5) 207 (30.0)
Black 2 (0.3) 0 (0.0) 0 (0.0) 2 (0.3)
Missinga 82 (12.9) 47 (11.1) 4 (9.8) 80 (11.6)
Ex or current smoker, n (%) 464 (72.7) 301 (71.2) 26 (63.4) 501 (72.6)
Weight, kg, mean (SD) 79.2 (16.6) 78.6 (16.5) 78.8 (17.6) 78.2 (16.1)
Body mass index, kg/m2, mean (SD) 28.1 (4.6) 27.6 (4.6) 27.1 (5.3) 27.5 (4.4)
FVC, mL, mean (SD) 2714 (757) 2728 (810) 1602 (330) 2683 (790)
FVC, % predicted, mean (SD) 79.7 (17.6) 79.3 (18.2) 45.0 (4.6) 78.0 (17.9)
FEV1/FVC, mean (SD)
b 81.7 (6.0) 81.7 (5.8) 86.6 (7.4) 81.3 (6.5)
Based on data collected at start of INPULSIS or INPULSIS-ON
a In France, regulation did not permit the collection of data on race
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(a) (b)Fig. 1 a absolute change in
FVC from baseline to week 48
of INPULSIS-ON, b relative
change in FVC from baseline to
week 48 of INPULSIS-ON
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impaired FVC represent a patient group that require care in
clinical practice [14]. Some physicians are already using
antifibrotic drugs in patients with FVC\50 % predicted,
based on regulatory authorities approving these drugs
without restriction based on FVC [6, 7], but many physi-
cians believe that the benefits of antifibrotic treatment
would likely be reduced, and the side-effects worse, in
patients with more advanced disease.
Subgroup analyses of pooled data from the INPULSIS
trials have demonstrated a consistent effect of nintedanib
on FVC decline in patients with baseline FVC B70 %
versus [70 % predicted, B80 % versus [80 % predicted
and B90 % versus [90 % predicted [15–17], suggesting
that nintedanib is effective in reducing progression of IPF
irrespective of the stage of disease at which it is initiated.
The latest international clinical practice guideline for IPF
highlights that there is no evidence to suggest an optimal
duration of therapy or a point at which therapy would no
longer be efficacious [8].
As with all data from open-label extension trials, these
results have limitations, including bias in the population
who completed the randomised placebo-controlled trials
and elected to continue in the open-label extension and the
lack of a placebo comparator in the extension phase.
Findings from this subgroup analysis should be interpreted
with caution as the number of patients with FVC B50 %
predicted at the start of INPULSIS-ON was small.
In conclusion, in an interim analysis of data from the
INPULSIS-ON open-label extension trial, the decline in
FVC in patients with baseline FVC B50 % and [50 %
predicted was similar to that in patients treated with nin-
tedanib in INPULSIS, suggesting a similar benefit on
disease progression, and no new safety signals were
identified.







predicted (n = 41)
FVC[50 % predicted
(n = 690)
Any adverse event(s) 609 (95.5) 379 (89.6) 41 (100.0) 649 (94.1)
Most frequent adverse event(s)a
Diarrhoea 398 (62.4) 78 (18.4) 19 (46.3) 446 (64.6)
Nausea 156 (24.5) 28 (6.6) 7 (17.1) 111 (16.1)
Cough 85 (13.3) 57 (13.5) 7 (17.1) 114 (16.5)
Nasopharyngitis 87 (13.6) 68 (16.1) 3 (7.3) 100 (14.5)
Bronchitis 67 (10.5) 45 (10.6) 4 (9.8) 97 (14.1)
Dyspnoea 49 (7.7) 48 (11.3) 10 (24.4) 88 (12.8)
Progression of IPFb 64 (10.0) 61 (14.4) 14 (34.1) 104 (15.1)
Weight decreased 62 (9.7) 15 (3.5) 7 (17.1) 75 (10.9)
Severe adverse event(s)c 174 (27.3) 99 (23.4) 21 (51.2) 210 (30.4)
Serious adverse event(s)d 194 (30.4) 127 (30.0) 26 (63.4) 271 (39.3)
Fatal adverse event(s) 37 (5.8) 31 (7.3) 9 (22.0) 66 (9.6)
Adverse event(s) leading to treatment discontinuatione 123 (19.3) 55 (13.0) 17 (41.5) 155 (22.5)
Diarrhoea 28 (4.4) 1 (0.2) 2 (4.9) 37 (5.4)
Progression of IPFb 13 (2.0) 21 (5.0) 7 (17.1) 37 (5.4)
Nausea 13 (2.0) 0 (0.0) 1 (2.4) 5 (0.7)
Fatigue 1 (0.2) 1 (0.2) 1 (2.4) 3 (0.4)
Weight decreased 6 (0.9) 1 (0.2) 1 (2.4) 6 (0.9)
Decreased appetite 9 (1.4) 1 (0.2) 0 (0.0) 3 (0.4)
a Adverse events reported in[12 % of patients in either treatment group in INPULSIS and/or in the overall patient population in INPULSIS-
ON
b Corresponds to the MedDRA term ‘IPF’, which included disease worsening and acute exacerbations of IPF
c Events that were incapacitating or that caused an inability to work or to perform usual activities
d Events that resulted in death, were immediately life threatening, resulted in persistent or clinically significant disability or incapacity, required
or prolonged hospitalisation, were related to a congenital anomaly or birth defect, or were deemed serious for any other reason
e Adverse events that led to permanent treatment discontinuation in C1 % of patients in the nintedanib or placebo group in INPULSIS and/or in
the overall patient population in INPULSIS-ON
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